Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A promising gene therapy for a rare inherited eye disease just cleared a major hurdle. Beacon Therapeutics announced that laru-zova significantly improved low-light reading ability in a Phase 3 trial for X-linked retinitis pigmentosa (XLRP) — a condition with no approved treatments. The company is now heading into talks with global regulators about a marketing application.
A promising gene therapy for a rare inherited eye disease just cleared a major hurdle. Beacon Therapeutics announced that its experimental therapy, laru-zova, met the primary endpoint of its pivotal Phase 3 trial for X-linked retinitis pigmentosa (XLRP) — a progressive inherited eye disease that primarily affects boys and young men, starting with night blindness and gradually narrowing peripheral vision.
In the 12-month trial, a significant proportion of treated patients improved their ability to read at least 15 additional letters in low-light conditions, while zero participants in the untreated control group achieved the same result. Beacon's CEO noted this makes them the only company to have a positive Phase 3 primary endpoint readout in this space — a meaningful competitive edge as they prepare to engage global regulators about a marketing application.
By the Numbers:
Why it matters: XLRP currently has no approved treatments, leaving patients with few options as their vision progressively deteriorates. A successful regulatory submission could bring the first-ever therapy to market for this underserved population.
